Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

11. november 2026 oppdatert av: Aligos Therapeutics

A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

55

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Aligos Therapeutics
  • Telefonnummer: 800-466-6059
  • E-post: info@aligos.com

Studiesteder

    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53704
        • Aligos Investigational Site
        • Ta kontakt med:
          • Aligos Investigational Site
          • Telefonnummer: 800-466-6059
          • E-post: info@aligos.com

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 60 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria: Key Inclusion Criteria

  1. Parts A and B only: Male or female between 18 and 60 years of age
  2. Part C only: Males between 18 and 55 years of age.
  3. Body mass index between 18.0 kg/m2 and 32.0 kg/m2
  4. In good health, as determined by no clinically significant findings from medical history, 12-lead ECG and vital signs measurements, and clinical laboratory assessments.
  5. Part C only: History of a minimum of 1 bowel movement per day.

Exclusion Criteria: Key Exclusion Criteria:

  1. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).

  2. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee).

  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs.

  4. Confirmed systolic blood pressure >140 or <90 mmHg, diastolic blood pressure >90 or <50 mmHg, or pulse rate >100 or <40 beats per minute.

  5. Positive hepatitis panel and/or positive human immunodeficiency virus test.

  6. Parts A and B only: Any of the following at screening or check-in:

    1. QTcF >450 ms in males or >470 ms in females
    2. QRS duration >120 ms
    3. PR interval >210 ms
    4. findings which would make QTc measurements difficult or QTc data uninterpretable
  7. Administration of any vaccine within 30 days prior to dosing.

  8. Use or intend to use any prescription medications/products, other than hormone replacement therapy, within 14 days prior to dosing

  9. Alcohol consumption of >21 units per week for males and >14 units per week for females, as applicable.

  10. Positive urine drug screen at screening or positive alcohol test result or positive urine drug screen at check-in.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: ALG-000184

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of ALG-000184

Placebo komparator: Placebo

Oral tablet(s) of placebo in HV participants once daily for up to 10 days

Single or multiple doses of Placebo

Annen: [14C]ALG-000184

Single oral dose of [14C]ALG-000184

Single micodose of [13C7,15N1]ALG-001075 with combination of [14C]ALG-000184

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and Tolerability (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-∞

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-tlast

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including AUC0-τ

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including Cmax

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including tmax t1/2

From enrollment to end of treatment at 10 days
PK Parameters (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters of ALG-001075 and ALG-000302, including ARAUC

From enrollment to end of treatment at 10 days
Total radioactivity recovery (fet1-t2) in urine and feces (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

determine the routes, rates of elimination, and mass balance of total radioactivity following a single oral dose of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Metabolic profiles of ALG-000184 (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

Determine, where possible, the metabolite profiles in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Identification of ALG-000184 (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

Determine, where possible, the chemical structure of major metabolites in plasma, urine, and feces following administration of [14C]ALG-000184

From enrollment to end of treatment at 10 days
Bioavailability of ALG-001075 (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

Determine the absolute bioavailability of ALG-001075 following oral administration of [14C]ALG-000184 relative to IV administration of [13C7,15N1]ALG-001075

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-∞

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including AUC0-tlast

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including Cmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including tmax

From enrollment to end of treatment at 10 days
PK parameters (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

PK parameters for ALG-001075 and [13C7,15N1]ALG-001075 in plasma and total radioactivity in plasma and whole blood including t1/2

From enrollment to end of treatment at 10 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
QTc (Part A and B)
Tidsramme: From enrollment to end of treatment at 10 days

Evaluate the effect of single and multiple (if applicable) oral doses of ALG-000184 on QTc in healthy participants

From enrollment to end of treatment at 10 days
Safety and Tolerability (Part C)
Tidsramme: From enrollment to end of treatment at 10 days

Number of participants with Incidence and severity of adverse events, 12-lead electrocardiogram parameters, and abnormal clinical laboratory results

From enrollment to end of treatment at 10 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

14. desember 2026

Primær fullføring (Antatt)

6. august 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ALG-000184-209

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .